Prospective, Observational Practice Survey of Applied Skin Care and Management of Cetuximab-related Skin Reactions: PROSKIN Study

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2019 Aug 25

PMID 31444619

Citations 2

Authors

Sacha I Rothschild

Daniel Betticher

Reinhard Zenhausern

Sandro Anchisi

Roger Von Moos

Miklos Pless

Peter Moosmann

Razvan A Popescu

Antonello Calderoni

Marco Dressler

Daniel Rauch

Stefanie Pederiva

Regina Woelky

Claudia Papet

Vera Buhler

Markus Borner

Affiliations

Soon will be listed here.

Abstract

Purpose: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).

Methods: This open-label, prospective observational study was conducted in Switzerland.

Results: A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.3 years; 73.6% males). The frequency of acneiform rash grade ≥ 2 increased from 12.6% at week 2 to 21.7% at week 16. The proportion of patients who reported no skin reaction decreased from 75.6% at week 2 to 43.3% at week 16. The most frequently used skin products at any time of observation were moisturizing (77.6%), lipid-regenerating (56.8%) or urea-containing products (52%), systemic antibiotics (49.6%), and vitamin K1 cream (43.2%). There was no clear effectiveness pattern for all product classes: in given patients, either the product showed no effect at all or a moderate/strong effect, consistently over time.

Conclusions: A great variety of low-cost general skin care products were commonly used. According to physician's preference, systemic antibiotics and vitamin K1 cream are an appropriate approach to prevent or treat cetuximab-related skin toxicity.

Citing Articles

The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients.

Mihai M, Ion A, Giurcaneanu C, Nitipir C, Popa A, Chifiriuc M J Clin Med. 2021; 10(15).

PMID: 34362003 PMC: 8347035. DOI: 10.3390/jcm10153219.

Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report.

Taira K, Fujiwara K, Fukuhara T, Morisaki T, Koyama S, Donishi R Yonago Acta Med. 2020; 63(4):379-384.

PMID: 33253347 PMC: 7683911. DOI: 10.33160/yam.2020.11.020.

References

Duffour J, Thezenas S, Dereure O, Garcin A, Caron J, Samalin E . Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer. 2010; 46(18):3169-74. DOI: 10.1016/j.ejca.2010.03.008. View

Su X, Lacouture M, Jia Y, Wu S . Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009; 77(2):124-33. DOI: 10.1159/000229752. View

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

Jaka A, Gutierrez-Rivera A, Lopez-Pestana A, Del Alcazar E, Zubizarreta J, Vildosola S . Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity. Actas Dermosifiliogr. 2015; 106(6):483-92. DOI: 10.1016/j.ad.2015.01.006. View

Lacouture M, Anadkat M, Bensadoun R, Bryce J, Chan A, Epstein J . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-95. PMC: 3128700. DOI: 10.1007/s00520-011-1197-6. View

Pinto C, Barone C, Girolomoni G, Russi E, Merlano M, Ferrari D . Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011; 16(2):228-38. PMC: 3228080. DOI: 10.1634/theoncologist.2010-0298. View

Ocvirk J, Cencelj S . Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2009; 24(4):453-9. DOI: 10.1111/j.1468-3083.2009.03446.x. View

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Jo J, Hong Y, Kim K, Lee J, Kim H, Lee M . Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol. 2012; 23(1):77-82. DOI: 10.1684/ejd.2012.1899. View

10.

Pinto C, Barone C, Girolomoni G, Russi E, Merlano M, Ferrari D . Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol. 2016; 39(4):407-15. DOI: 10.1097/COC.0000000000000291. View

11.

Petrelli F, Borgonovo K, Barni S . The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013; 8(3):173-181. DOI: 10.1007/s11523-013-0257-x. View

12.

Frampton J . Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs. 2010; 70(15):1987-2010. DOI: 10.2165/11205010-000000000-00000. View

13.

Pinta F, Ponzetti A, Spadi R, Fanchini L, Zanini M, Mecca C . Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013; 13(1):62-7. DOI: 10.1016/j.clcc.2013.10.001. View

14.

Scope A, Lieb J, Dusza S, Phelan D, Myskowski P, Saltz L . A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol. 2009; 61(4):614-20. DOI: 10.1016/j.jaad.2009.03.046. View

15.

Delgado-Rodriguez M, Llorca J . Bias. J Epidemiol Community Health. 2004; 58(8):635-41. PMC: 1732856. DOI: 10.1136/jech.2003.008466. View

16.

Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-17. DOI: 10.1056/NEJMoa0805019. View

17.

Bonomo P, Loi M, Desideri I, Olmetto E, Paoli C, Terziani F . Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol. 2017; 120:98-110. DOI: 10.1016/j.critrevonc.2017.10.011. View

18.

Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A . Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Dermatology. 2010; 220(3):243-8. DOI: 10.1159/000277430. View

19.

Scope A, Agero A, Dusza S, Myskowski P, Lieb J, Saltz L . Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007; 25(34):5390-6. DOI: 10.1200/JCO.2007.12.6987. View